pyridostigmine bromide has been researched along with cyclopentane in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alkalay, D; Chapman, S; Cohen, G; Gilat, E; Rabinovitz, I; Raveh, L; Weissman, BA | 1 |
| Abraham, S; Cohen, G; Dachir, S; Gilat, E; Herskovitz, M; Kapon, J; Levy, A; Raveh, L; Teitelbaum, Z | 1 |
2 other study(ies) available for pyridostigmine bromide and cyclopentane
| Article | Year |
|---|---|
The involvement of the NMDA receptor complex in the protective effect of anticholinergic drugs against soman poisoning.
Topics: Animals; Brain; Cholinesterase Inhibitors; Cyclopentanes; Dizocilpine Maleate; Dose-Response Relationship, Drug; Drug Interactions; Electroencephalography; Excitatory Amino Acid Antagonists; Flunitrazepam; In Vitro Techniques; Male; Mice; Mice, Inbred ICR; Parasympatholytics; Protein Binding; Pyridostigmine Bromide; Rats; Rats, Sprague-Dawley; Receptors, GABA-A; Receptors, Glutamate; Receptors, N-Methyl-D-Aspartate; Scopolamine; Seizures; Soman; Time Factors | 1999 |
Extrapolating from animal studies to the efficacy in humans of a pretreatment combination against organophosphate poisoning.
Topics: Animals; Chemical Warfare Agents; Cholinergic Antagonists; Cyclopentanes; Disease Models, Animal; Dogs; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Lethal Dose 50; Male; Metabolic Clearance Rate; Organophosphate Poisoning; Organophosphates; Papio anubis; Poisoning; Pyridostigmine Bromide; Sarin; Species Specificity; Treatment Outcome | 2007 |